About Astrazeneca
Astrazeneca is a company based in Cambridge (United Kingdom) founded in 1913.. The company has 94,300 employees as of December 31, 2024. Astrazeneca has completed 23 acquisitions, including Acerta Pharma, Alexion and Amolyt Pharma. Astrazeneca offers products and services including Enhertu and Cardiovascular Medicines. Astrazeneca operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Headquarter Cambridge, United Kingdom
- Employees 94300 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Astrazeneca Plc
-
Annual Revenue
$53.02 B (USD)14.82as on Dec 31, 2024
-
Net Profit
$6.9 B (USD)14.92as on Dec 31, 2024
-
EBITDA
$17.5 B (USD)21.08as on Dec 31, 2024
-
Latest Funding Round
$6.09 M (USD), Post-IPO
Dec 27, 2021
-
Investors
European Union
& 5 more
-
Employee Count
94300
as on Dec 31, 2024
-
Investments & Acquisitions
Acerta Pharma
& 22 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Astrazeneca
Astrazeneca is a publicly listed company on the NSE with ticker symbol ASTRAZEN in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Astrazeneca
Astrazeneca offers a comprehensive portfolio of products and services, including Enhertu and Cardiovascular Medicines. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets HER2-positive metastatic breast cancer through antibody-drug conjugates.
Addresses heart, renal, and metabolic conditions via innovative research.
Unlock access to complete
Unlock access to complete
Leadership Team
403 people
Software Development Team
205 people
Product Management Team
76 people
Data Analysis and Operations Team
68 people
Senior Team
67 people
Human Resources and Administration
63 people
Sales and Marketing
54 people
Operations Team
50 people
Unlock access to complete
Funding Insights of Astrazeneca
- Total Funding Total Funding
- Total Rounds 27
- Last Round Post-IPO — $6.1M
-
First Round
First Round
(05 Jan 2011)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2021 | Amount | Post-IPO - Astrazeneca | Valuation |
investors |
|
| May, 2021 | Amount | Grant - Astrazeneca | Valuation |
investors |
|
| Jan, 2021 | Amount | Grant - Astrazeneca | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Astrazeneca
Astrazeneca has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Cambridge and USAGov. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC firm for early-stage startups
|
Founded Year | Domain | Location | |
|
US tech companies are funded across stages by Columbia Capital.
|
Founded Year | Domain | Location | |
|
Investment research services are provided to financial clients by Cambridge.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Astrazeneca
Astrazeneca has strategically engaged in corporate development activities, having acquired 23 companies. Notable acquisitions include Acerta Pharma, Alexion and Amolyt Pharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Develops AI models for pathology diagnostics and biomedical image analysis.
|
2024 | ||||
|
Developer of in vivo adoptive cell therapies for cancer and autoimmune diseases. This involves engineering immune cells directly within the patient's body, eliminating the need for complex ex vivo manufacturing and reducing the risks associated with traditional cell therapies. The company utilizes a proprietary vector platform to enable single-injection, off-the-shelf treatments, simplifying treatment logistics and reducing costs. The therapies are designed to minimize immune rejection and graft-versus-host disease, improving patient accessibility and quality of life. The platform is scalable, ensuring high-yield and high-purity production.
|
2020 | ||||
|
Therapeutics for cardio-renal diseases, including hypertension treatments, are developed.
|
2018 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Astrazeneca
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Astrazeneca Comparisons
Competitors of Astrazeneca
Astrazeneca operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| domain | founded_year | HQ Location |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| domain | founded_year | HQ Location |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| domain | founded_year | HQ Location |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for the treatment of multiple disorders
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Astrazeneca
Frequently Asked Questions about Astrazeneca
When was Astrazeneca founded?
Astrazeneca was founded in 1913 and raised its 1st funding round 98 years after it was founded.
Where is Astrazeneca located?
Astrazeneca is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Who is the current CEO of Astrazeneca?
Pascal Soirot is the current CEO of Astrazeneca.
How many employees does Astrazeneca have?
As of Dec 31, 2024, the latest employee count at Astrazeneca is 94,300.
What is the annual revenue of Astrazeneca?
Annual revenue of Astrazeneca is $53.02B as on Dec 31, 2024.
What does Astrazeneca do?
AstraZeneca was established in 1913 and operates as a multinational pharmaceutical and biologics firm headquartered in Cambridge, United Kingdom. Operations span over 100 countries, with a focus on products addressing cancer, cardiovascular, gastrointestinal, infectious, neurological, respiratory, and inflammatory conditions. The company has grown through mergers and acquisitions, including Cambridge Antibody Technology in 2006 and MedImmune in 2007, achieving annual revenues of 43.85 billion in 2022.
Who are the top competitors of Astrazeneca?
Astrazeneca's top competitors include Merck, Roivant Sciences and AbbVie.
What products or services does Astrazeneca offer?
Astrazeneca offers Enhertu and Cardiovascular Medicines.
Is Astrazeneca publicly traded?
Yes, Astrazeneca is publicly traded on NSE under the ticker symbol ASTRAZEN.
How many acquisitions has Astrazeneca made?
Astrazeneca has made 23 acquisitions, including Acerta Pharma, Alexion, and Amolyt Pharma.
Who are Astrazeneca's investors?
Astrazeneca has 6 investors. Key investors include European Union, Cambridge, USAGov, Public Health Emergency, and Mission Ventures.
What is Astrazeneca's ticker symbol?
The ticker symbol of Astrazeneca is ASTRAZEN on NSE.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.